Biomarkers /
CYP2D6
Overview
CYP2D6 is altered in 2.44% of all cancers with endometrial endometrioid adenocarcinoma, low grade ovarian serous adenocarcinoma, breast invasive ductal carcinoma, cervical squamous cell carcinoma, and colon adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in CYP2D6 are CYP2D6 K281del (10.71%), CYP2D6 E410K (0.39%), CYP2D6 A163T (0.22%), CYP2D6 A165T (0.22%), and CYP2D6 A235V (0.85%) [3].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.